J.M. Foidart is an MD, PhD trained in obstetrics and gynecology (Ob-Gyn), in part in the United States (1976-1979) at the Johns Hopkins University Hospital, Baltimore, and in Belgium, Finland and France. He spent 3 years as a biochemist at the National Institutes of Health in Bethesda, Maryland, USA. In 1988, he became professor and chairman of the Department of Cell Biology at the University of Liege (ULg), Belgium. He then established a large and renowned laboratory that owns many patents. From 1989 until 1996, he contributed to the clinical development of the first oral contraceptive containing drospirenone. In 1996, he became chairman of the Department of Ob-Gyn ULg until 2012. From 2012 until 2015, he was extraordinary Professor at University of Liège, Belgium and chairman of the Interdisciplinary Group of Genomics and Proteomics (600 researchers). He is presently a board member and the chairman of the Scientific Board at MITHRA, a Belgian company that he cocreated in 1999. His main research interest is in experimental reproductive endocrinology and oncology. He is a member of many national and international scientific committees. He is a past president of the Belgian Society of Biology and of the Belgian Society of Gynecology. He is past General Secretary of the European Society of Gynecology and a former Board member at FIGO and presently a member of the Board of the International Society of Gynecological Endocrinology.